MX9101237A - Xantinas substituidas y procedimiento para su preparacion - Google Patents

Xantinas substituidas y procedimiento para su preparacion

Info

Publication number
MX9101237A
MX9101237A MX9101237A MX9101237A MX9101237A MX 9101237 A MX9101237 A MX 9101237A MX 9101237 A MX9101237 A MX 9101237A MX 9101237 A MX9101237 A MX 9101237A MX 9101237 A MX9101237 A MX 9101237A
Authority
MX
Mexico
Prior art keywords
preparation procedure
substituted xanthines
xanthines
substituted
procedure
Prior art date
Application number
MX9101237A
Other languages
English (en)
Inventor
Derek Richard Buckle
David Glynn Smith
Ashley Edward Fenwick
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of MX9101237A publication Critical patent/MX9101237A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX9101237A 1990-09-26 1991-09-24 Xantinas substituidas y procedimiento para su preparacion MX9101237A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020959A GB9020959D0 (en) 1990-09-26 1990-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
MX9101237A true MX9101237A (es) 1992-05-04

Family

ID=10682788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9101237A MX9101237A (es) 1990-09-26 1991-09-24 Xantinas substituidas y procedimiento para su preparacion

Country Status (12)

Country Link
EP (1) EP0550570A1 (es)
JP (1) JPH06501251A (es)
KR (1) KR930702351A (es)
AU (1) AU653364B2 (es)
CA (1) CA2092430A1 (es)
GB (1) GB9020959D0 (es)
IE (1) IE913350A1 (es)
MX (1) MX9101237A (es)
NZ (1) NZ239921A (es)
PT (1) PT99062A (es)
WO (1) WO1992005175A1 (es)
ZA (1) ZA917610B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132291T2 (de) * 1990-12-21 2000-12-14 Beecham Group P.L.C., Brentford Xanthinderivate
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
DE69531506T2 (de) * 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
WO1996036638A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use
DZ2629A1 (fr) * 1997-10-23 2003-03-08 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline procédé pour leur préparation et compositions les contenant.
RU2003103103A (ru) * 2000-07-04 2004-08-20 Ново Нордиск А/С (DK) Гетероциклические соединения, которые являются ингибиторами фермента dpp-iv
EP1301187B1 (en) * 2000-07-04 2005-07-06 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE395349T1 (de) 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ES2284056T3 (es) * 2003-07-31 2007-11-01 Schering Corporation Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil.
WO2005058898A2 (en) * 2003-12-16 2005-06-30 Ranbaxy Laboratories Limited Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004037554A1 (de) 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039507A1 (de) * 2004-08-14 2006-03-02 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkoxi-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20200028498A (ko) 2010-06-24 2020-03-16 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT392968B (de) * 1987-01-30 1991-07-25 Sandoz Ag Neue xanthinderivate
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
WO1992007852A1 (en) * 1990-10-25 1992-05-14 G.D. Searle & Co. Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders

Also Published As

Publication number Publication date
EP0550570A1 (en) 1993-07-14
CA2092430A1 (en) 1992-03-27
JPH06501251A (ja) 1994-02-10
WO1992005175A1 (en) 1992-04-02
GB9020959D0 (en) 1990-11-07
KR930702351A (ko) 1993-09-08
AU653364B2 (en) 1994-09-29
ZA917610B (en) 1992-09-30
NZ239921A (en) 1993-12-23
AU8541391A (en) 1992-04-15
IE913350A1 (en) 1992-04-08
PT99062A (pt) 1992-08-31

Similar Documents

Publication Publication Date Title
MX9101237A (es) Xantinas substituidas y procedimiento para su preparacion
MX24568A (es) 3-arilcarbonil-1h-indoles y procedimiento para su preparacion.
MX174176B (es) Compuestos azo y procedimiento para su preparacion
MX9205279A (es) Derivados de benzanilida y procedimiento para su preparacion
MX9205278A (es) Derivados de benzanilida y procedimiento para su preparacion
MX25829A (es) Mezclas de polisacaridos sulfatados y procedimiento para su preparacion.
MX9845A (es) Propanaminas 3-ariloxi-3-substituidas y procedimiento para su preparacion.
MX9101793A (es) Derivados de tiazolidindiona y procedimiento para su preparacion
MX9101235A (es) Xantinas substituidas y procedimiento para su preparacion
MX9100388A (es) Derivados de carboximetilciclopropano y procedimiento para su preparacion
MX9201780A (es) Eteres oximicos y procedimiento para su preparacion.
MX9205316A (es) Sulfonilaminocarboniltriazolinonas y procedimiento para su obtencion
MX9100811A (es) Indolonaftiridinas y procedimiento para su preparacion
MX9100845A (es) Nuevas tienodiazepinas y procedimiento para su preparacion
MX9100415A (es) Piridinas substituidas y procedimiento para su obtencion
MX9101516A (es) Derivados de 1,2,5,6-tetrahidropiridin 3-cetoxima y-3-aldoxina y procedimiento para su preparacion
MX21243A (es) Indenoindoles y procedimiento para su preparacion.
MX164079B (es) 3-aroiloxifenilcarbamatos polimerizables y metodos para su preparacion y uso
MX9205747A (es) Pirazolinas y procedimiento para su preparacion.
MX7829A (es) Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
MX9205746A (es) Pirazolinas y procedimiento para su preparacion.
MX9102583A (es) Microgranallas para vidriado y procedimiento para su obtencion.
MX9100367A (es) Derivados de heteroarilcetona y procedimiento para su preparacion
MX162953B (es) Articulo fotosensible y procedimiento para su preparacion
MX9101794A (es) Compuestos de trifendioxazina y procedimiento para su preparacion

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees